New Concepts for Targeted Systemic Therapy in Breast Cancer

被引：15

作者：

Liedtke, C. ^{[1
]}

Wolf, M. K. ^{[1
]}

Kiesel, L. ^{[1
]}

机构：

[1] Univ Klinikum Munster, Klin & Poliklin Frauenheilkunde & Geburtshilfe, D-48149 Munster, Germany

来源：

GEBURTSHILFE UND FRAUENHEILKUNDE | 2010年 / 70卷 / 08期

关键词：

molecular heterogeneity; targeted therapies; triple negative; molecular subclass; small molecules; DOUBLE-BLIND; PHASE-III; TRASTUZUMAB; WOMEN; COMBINATION; RECEPTOR; HER2; FULVESTRANT; SURVIVAL; EFFICACY;

D O I：

10.1055/s-0030-1250182

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Breast cancer is characterized by a fundamental heterogeneity, the extent of which has been demonstrated in numerous scientific studies. Currently, breast cancer is divided into three major subgroups: luminal, Her-2 positive, and triple negative breast cancer. Despite considerable advances in the therapy of patients with breast cancer, further optimization of current therapeutic strategies is necessary and possible. While the therapy of luminal and Her-2 positive breast cancers focuses on preventing and overcoming tumoral resistance, research into triple negative breast cancer concentrates on developing and establishing novel targeted therapeutic agents.

引用

页码：625 / 633

页数：9

共 45 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2]

[Anonymous], CANC RES S

[3]

Baselga J, 2009, CANCER RES, V69, p497S

[4] Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma [J].

Bendell, JC ;

Domchek, SM ;

Burstein, HJ ;

Harris, L ;

Younger, J ;

Kuter, I ;

Bunnell, C ;

Rue, M ;

Gelman, R ;

Winer, E .

CANCER, 2003, 97 (12) :2972-2977

[5]

Bergh J, 2009, CANCER RES, V69, p490S

[6]

Blackwell KL, 2009, CANCER RES, V69, p499S

[7] Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients [J].

Byrski, T. ;

Huzarski, T. ;

Dent, R. ;

Gronwald, J. ;

Zuziak, D. ;

Cybulski, C. ;

Kladny, J. ;

Gorski, B. ;

Lubinski, J. ;

Narod, S. A. .

BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (02) :359-363

[8] A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses [J].

Cameron, David ;

Casey, Michelle ;

Press, Michael ;

Lindquist, Deborah ;

Pienkowski, Tadeusz ;

Romieu, C. Gilles ;

Chan, Stephen ;

Jagiello-Gruszfeld, Agnieszka ;

Kaufman, Bella ;

Crown, John ;

Chan, Arlene ;

Campone, Mario ;

Viens, Patrice ;

Davidson, Neville ;

Gorbounova, Vera ;

Raats, Johannes Isaac ;

Skarlos, Dimosthenis ;

Newstat, Beth ;

Roychowdhury, Debasish ;

Paoletti, Paolo ;

Oliva, Cristina ;

Rubin, Stephen ;

Stein, Steven ;

Geyer, Charles E. .

BREAST CANCER RESEARCH AND TREATMENT, 2008, 112 (03) :533-543

[9] The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes [J].

Carey, Lisa A. ;

Dees, E. Claire ;

Sawyer, Lynda ;

Gatti, Lisa ;

Moore, Dominic T. ;

Collichio, Frances ;

Ollila, David W. ;

Sartor, Carolyn I. ;

Graham, Mark L. ;

Perou, Charles M. .

CLINICAL CANCER RESEARCH, 2007, 13 (08) :2329-2334

[10] Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer [J].

Clayton, AJ ;

Danson, S ;

Jolly, S ;

Ryder, WDJ ;

Burt, PA ;

Stewart, AL ;

Wilkinson, PM ;

Welch, RS ;

Magee, B ;

Wilson, G ;

Howell, A ;

Wardley, AM .

BRITISH JOURNAL OF CANCER, 2004, 91 (04) :639-643

← 1 2 3 4 5 →